Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$2.27 USD
-0.04 (-1.73%)
Updated May 10, 2024 04:00 PM ET
After-Market: $2.27 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for Cyclacel Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 26 | 28 | 23 | 11 | 10 |
Income After Depreciation & Amortization | -25 | -28 | -23 | -11 | -10 |
Non-Operating Income | 0 | 2 | 0 | 1 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -26 | -26 | -23 | -10 | -9 |
Income Taxes | -3 | -5 | -4 | -1 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -23 | -21 | -19 | -8 | -8 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -23 | -21 | -19 | -8 | -8 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -25 | -28 | -23 | -11 | -10 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -25 | -28 | -23 | -11 | -10 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.85 | 0.75 | 0.60 | 0.21 | NA |
Diluted EPS Before Non-Recurring Items | -26.75 | -28.49 | -32.08 | -58.02 | -167.92 |
Diluted Net EPS (GAAP) | -26.75 | -28.49 | -32.08 | -51.27 | -146.93 |
Fiscal Year end for Cyclacel Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.03 | 0.02 | 0.37 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.03 | 0.02 | 0.37 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 5.39 | 6.87 | 6.31 | 7.32 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -5.36 | -6.85 | -5.94 | -7.32 |
Non-Operating Income | NA | -0.33 | 0.15 | -0.11 | 0.20 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -5.69 | -6.70 | -6.03 | -7.12 |
Income Taxes | NA | -0.42 | -0.67 | -0.59 | -1.32 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.27 | -6.03 | -5.45 | -5.80 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.27 | -6.03 | -5.45 | -5.80 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 0.85 | 0.84 | 0.84 | 0.84 |
Diluted EPS Before Non-Recurring Items | NA | -6.23 | -7.35 | -6.60 | -7.05 |
Diluted Net EPS (GAAP) | NA | -5.91 | -7.20 | -6.60 | -7.05 |